Drug intelligence / Profile preview

ticlopidine + itraconazole

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

A combination of ticlopidine and itraconazole. Ticlopidine is a platelet aggregation inhibitor that works by preventing binding of adenosine diphosphate (ADP) to its platelet receptor, impairing ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Itraconazole is an antifungal medication that acts as a CYP3A inhibitor. When used together, these drugs can affect the metabolism of other medications through their effects on different cytochrome P450 enzymes.

Targets

CYP2B6 (Cytochrome P450 2B6)P2Y (P2Y receptors)CYP3A7 (Cytochrome P450 3A7)

Beyond the preview

Go deeper on ticlopidine + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ticlopidine + itraconazole.

Explore the full profile